Daclatasvir, sold under the brand name Daklinza, is an antiviral medication used in combination with other medications to treat hepatitis C (HCV).[5] The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis.[3] It is taken by mouth.[5]
Common side effects when used with sofusbivir and daclatasvir include headache, feeling tired, and nausea.[4] With daclatasvir, sofosbuvir, and ribavirin the most common side effects are headache, feeling tired, nausea, and red blood cell breakdown.[4] It should not be used with St. John's wort, rifampin, or carbamazepine.[5] It works by inhibiting the HCV protein NS5A.[3]
Daclatasvir was approved for use in the European Union in 2014, and the United States and India in 2015.[6] It is on the World Health Organization's List of Essential Medicines.[7]
The brand Daklinza is being withdrawn by Bristol Myers Squibb in countries where the drug is not typically prescribed, and Bristol Myers Squibb says it will not enforce its patents in those countries.[8]
^"Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^ abc"Daklinza film-coated tablets – Summary of Product Characteristics (SPC) - (eMC)". Electronic Medicines Compendium. September 2016. Archived from the original on 2016-11-09.
^ abcde"Daklinza (daclatasvir) tablets, for oral useInitial U.S. Approval: 2015". DailyMed. 16 October 2019. Retrieved 19 November 2021.
^ abc"Daclatasvir Dihydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 5 November 2016. Retrieved 6 December 2016.
^"Hepatitis C Treatment Snapshots: Daclatasvir" (PDF). amFAR TreatAsia. February 2016. Archived (PDF) from the original on 2016-09-03.
^World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^"Important information about the discontinuation of Daklinza". Bristol Myers Squibb. 9 March 2020. Retrieved 19 June 2020.
Daclatasvir, sold under the brand name Daklinza, is an antiviral medication used in combination with other medications to treat hepatitis C (HCV). The...
those who have been previously infected. In combination with ledipasvir, daclatasvir or simeprevir, it is not recommended with amiodarone due to the risk...
ledipasvir/sofosbuvir, or sofosbuvir/velpatasvir. Sofosbuvir with either daclatasvir or simeprevir may also be used. HCV genotype 1a (with compensated cirrhosis):...
post-marketing trial of beclabuvir, in combination with asunaprevir and daclatasvir, to study the combination's safety profile with regard to liver function...
act on dimers of NS5A. A number of modeling studies have shown that daclatasvir, which is an NS5A inhibitor, only binds to the "back-to-back" NS5A dimer...
interferon-free regimens with other direct-acting antiviral agents including daclatasvir. "Prescription medicines: registration of new chemical entities in Australia...
individual patients obtain legal access to generic versions of sofosbuvir, daclatasvir, and ledipasvir. At EASL International Liver Congress, Dr. Freeman presented...
hepatitis C drugs ledipasvir/sofosbuvir or sofosbuvir along with amiodarone, daclatasvir, or simeprevir developed abnormally slow heartbeats and one died of cardiac...
boceprevir, simeprevir, and others NS5A inhibitors, including ledipasvir, daclatasvir, and others NS5B inhibitors, including sofosbuvir, dasabuvir, and others...
Nguyen Tien (May 2018). "Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis"...
remissions in <50% of cases. More recently, drugs (e.g. simeprevir, daclatasvir, sofosbuvir, and dasabuvir) that directly inhibit the virus's reproduction...
in a FDC with paritaprevir and ritonavir, co-packaged with dasabuvir Daclatasvir, approved on July 24, 2015 Elbasvir, approved on January 28, 2016 in...
inhibitor ledipasvir was approved. Four other NS5A inhibitors of this class—daclatasvir, ombitasvir, elbasvir and velpatasvir—have been subsequently approved...
NS5A Y93H variant are less likely to respond to NS5A inhibitors such as daclatasvir, ledipasvir and ombitasvir, which are commonly used in popular DAA regimens...
including generic treatment including active substances - sofosbuvir, daclatasvir, ledipasvir, velpatasvir. The results of using antiviral therapy reach...
succeeded in the offering of variable DAAs (as sofosbuvir, simeprevir, daclatasvir, ombitasvir and paritaprevir, ledipasvir) in Egypt at affordable prices...
antibodies, Viremic persons received sofosbuvir (400 mg daily) plus daclatasvir (60 mg daily) with or without ribavirin for 12 or 24 weeks, Almost 50...
Global Information
